Related Experiment Video

Updated: Aug 9, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

New and emerging strategies for reducing cardiometabolic risk factors

Philip T Rodgers1, Dawn C Fuke

  • 1School of Pharmacy, University of North Carolina, Chapel Hill, USA. prodgers1@nc.rr.com

Pharmacotherapy
|April 28, 2006
PubMed

Insights

New drug therapies target multiple cardiometabolic risk factors for metabolic syndrome and coronary heart disease (CHD). These treatments address emerging risk factors like low HDL cholesterol and improve glucose metabolism, offering comprehensive cardiovascular health benefits.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Metabolic syndrome and coronary heart disease (CHD) are linked to multiple risk factors.
  • Emerging CHD risk factors include low high-density lipoprotein (HDL) cholesterol, apolipoprotein A-1 (apoA-1), high-sensitivity C-reactive protein, and small dense low-density lipoprotein particles.
  • Novel therapeutic strategies are being developed to address these complex risk profiles.

Purpose of the Study:

  • To review new and emerging drug therapies for cardiometabolic risk factors.
  • To describe the mechanisms of action and clinical trial findings for these agents.
  • To discuss established therapies with benefits for emerging CHD risk factors.

Main Methods:

  • Literature review of recent drug therapies and clinical trial data.
  • Analysis of mechanisms of action for novel agents.
  • Discussion of established drug classes including ACE inhibitors and ARBs.

Main Results:

  • Antiobesity agents reduce dyslipidemia and improve glucose metabolism.
  • Cholesteryl ester transfer protein inhibitors and glitazars increase HDL cholesterol and improve metabolic parameters.
  • Amylin analogs (pramlintide) and incretin mimetics (exenatide) aid weight reduction and glucose control.
  • Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) show insulin-sensitizing effects and improve glucose/lipid profiles, with telmisartan noted for specific benefits.

Conclusions:

  • Several new drug classes show promise in managing multiple cardiometabolic risk factors.
  • Emerging therapies offer novel approaches to address HDL cholesterol, glucose metabolism, and weight management.
  • Established drugs like ARBs also contribute to improved cardiometabolic profiles and may prevent type 2 diabetes.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Lifestyle Factors and Health01:20

Lifestyle Factors and Health

Lifestyle factors play a critical role in maintaining overall health and preventing chronic diseases. Key elements, such as regular physical activity, a nutritious diet, and abstinence from smoking, can significantly enhance physical, mental, and emotional well-being while reducing the risk of several life-threatening conditions.
Benefits of Physical Activity
Physical activity, whether through structured exercise or casual activities like walking, biking, or dancing, is a cornerstone of a...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...